RSS

Independent Data Monitoring Committee (IDMC)

The Independent Data Monitoring Committee (IDMC) has approved the continuation of the Phase III clinical study into OSE Immunotherapeutics’ treatment for Non-Small Cell Lung Cancer (NSCLC) — Tedopi — after immune checkpoint inhibitor treatment. more

News

Following a planned review, the Data Monitoring Committee (DMC) has recommended termination of the Phase Ib/II study of daratumumab in combination with atezolizumab versus atezolizumab monotherapy in patients with previously treated NSCLC more

News

Nanobiotix, a late-stage clinical nanomedicine company, has announced that the Independent Data Monitoring Committee (IDMC) has completed the interim evaluation of the Phase II/III trial results of NBTXR3 in soft tissue sarcoma. more

News